Travis Urban, MD
Neurology · San Francisco, CANPI 1750885893
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,187 of the $1,746 with a category attached, or 68.0%. Alnylam Pharmaceuticals Inc. accounts for 83.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,613 and has fallen 93.2% since, to $110 in 2025.
Across 20 payments — averaging $87.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1K
- Eisai Inc.$162
- Lilly USA, LLC$95
- Life Molecular Imaging Ltd$23
- AbbVie$16
What the payments were for
- Travel & lodging$1,18768%
- Food & beverage$55932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 9 | $1,450 |
| Eisai Inc. | 6 | $162 |
| Lilly USA, LLC | 3 | $95 |
| Life Molecular Imaging Ltd | 1 | $23 |
| AbbVie | 1 | $16 |
How this compares
$1,746 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 232 | $3,228 |
| Memantine Hcl ErMemantine Hcl | 13 | $2,675 |
| Rivastigmine | 15 | $1,899 |
| Escitalopram Oxalate | 73 | $964 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 31 | $754 |
| Quetiapine Fumarate | 42 | $645 |
| Memantine Hcl | 14 | $584 |
| Trazodone Hcl | 34 | $434 |
| Mirtazapine | 15 | $386 |
| Venlafaxine Hcl | 12 | $241 |
| Sertraline Hcl | 26 | $215 |
| Atorvastatin Calcium | 11 | $117 |
| Lorazepam | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.